The withdrawal of some COX-2 inhibitors, namely rofecoxib and valdecoxib, from the market contributed to raise anxiety and concerns about this class of drugs but also prompted a re-evaluation of the benefits (which are undisputed) and the risks (often forgotten in everyday clinical practice) of all selective and non-selective NSAIDs. This evidence concerns the gene PTGS2 and Anxiety.